PF-219,061

In the article presented below, the topic of PF-219,061 will be addressed from different perspectives and approaches. Its origins, its evolution over time and its importance today will be analyzed. In addition, its implications in various areas will be delved into, from the social to the scientific, including the cultural and economic aspects. We will seek to offer a comprehensive and global vision of PF-219,061, so that the reader can understand its relevance and influence in today's world. Through a multidisciplinary approach, we aim to delve into the different aspects that define PF-219,061, providing detailed and updated information on this broad and diverse topic.

Chemical compound

PF-219,061

Clinical data
Routes of administration	Nasal
Legal status
Legal status	Investigational (discontinued)
Identifiers
IUPAC name (R)-3-(4-propylmorpholin-2-yl)phenol
CAS Number	710654-74-3 Y
PubChem CID	9794475
ChemSpider	7970242 N
UNII	ZK5ZP8L5S2
CompTox Dashboard (EPA)	DTXSID90430791
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCN1CCO(C1)C2=CC(=CC=C2)O
InChI InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1 N Key:WYEGTIGJSHGEID-ZDUSSCGKSA-N N
NY (what is this?)  (verify)

PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D₃ receptor.^[1][2] It was under development as a potential medication for the treatment of female sexual dysfunction.^[3][4] It did not advance into clinical trials.^[5]

See also

• ABT-670
• ABT-724
• Cabergoline
• Bremelanotide
• Flibanserin
• Intrinsa
• Melanotan II
• OSU-6162
• PF-592,379
• Pramipexole
• Tibolone
• UK-414,495

References

1. ^ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, et al. (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691–6. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.
2. ^ Brioni JD, Moreland RB (2006). "Dopamine D4 receptors and the regulation of penile erection". Drug Discovery Today: Therapeutic Strategies. 3 (4): 599–604. doi:10.1016/j.ddstr.2006.10.006.
3. ^ Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO/2003/051370, granted to Pfizer^{[permanent dead link]}
4. ^ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I (July 2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39 (7): 523–33. doi:10.1080/00498250902893775. PMID 19480558. S2CID 26474660.
5. ^ Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V (July 2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies". Expert Opinion on Drug Discovery. 11 (7): 641–64. doi:10.1080/17460441.2016.1185413. PMID 27135354. S2CID 205917989.